Skip to main content
Toggle navigation
Login
Search
Home
Tweets by 2023 National Biotechnology Conference
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Poster Schedule
All Days
Mon, Apr 24
Tue, Apr 25
Poster Schedule
Type here to filter the list
Monday, April 24, 2023
10:30 AM – 11:30 AM
ET
(M1030-01-01) Measuring Free IgE in Low-Affinity Interaction with Omalizumab Using an Automated Microfluidic Immunoassay to Support Pharmacokinetics and Pharmacodynamics Studies
Favorite
10:30 AM – 11:30 AM
ET
(M1030-01-02) Identification and Characterization of Impurities in Lipid Nanoparticle Components Using TOF-MS with Predictive In Silico Fragmentation and Automated Data Processing
Favorite
10:30 AM – 11:30 AM
ET
(M1030-01-03) Monodisperse Fully Porous Particles (MFPP) for Use in Increasing Resolution in Liquid Chromatography
Favorite
10:30 AM – 11:30 AM
ET
(M1030-01-04) Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics Using In Silico and In Vitro Methods
Favorite
10:30 AM – 11:30 AM
ET
(M1030-01-05) Use of Technical Replicate Precision Acceptance for qPCR- and ddPCR-based Validations and Sample Testing
Favorite
10:30 AM – 11:30 AM
ET
(M1030-01-06) Investigating the Impact of a Soluble Target on ADA Measurements in a Bispecific Antibody Clinical Study
Favorite
10:30 AM – 11:30 AM
ET
(M1030-01-07) E. coli Nissle 1917-Based Bacterial Cell Therapy Helps Restore Intestinal Barrier and Improve Post-Myocardial Infarction Outcomes
Favorite
10:30 AM – 11:30 AM
ET
(M1030-01-08) Quantitation of Diazepam and Its Metabolites Using High-Throughput Rapidfire Mass Spectrometry
Favorite
11:30 AM – 12:30 PM
ET
(M1130-01-01) An Adjuvanted Microparticulate Microneedle-Based Gonorrhea Vaccine Induced a Robust Immune Response in Mice
Favorite
11:30 AM – 12:30 PM
ET
(M1130-01-02) Multiscale Pharmacokinetic Modeling and Simulation of Local and Systemic Exposure of Intramuscularly Injected LNPs
Favorite
11:30 AM – 12:30 PM
ET
(M1130-01-04) XenoImmune™ Mouse Model, a Novel and Proprietary Animal Model that Recapitulates Clinical Immunogenicity Rates of Biologics
Favorite
11:30 AM – 12:30 PM
ET
(M1130-01-05) Multi-factored Immunogenicity Risk Assessment Approach for Bispecific Immune Cell Engagers
Favorite
11:30 AM – 12:30 PM
ET
(M1130-01-06) Structural Profiling of mRNA Vaccine Constructs: Applications for mRNA Vaccine Design and Quality Assessment
Favorite
11:30 AM – 12:30 PM
ET
(M1130-01-07) Characterization of Critical Reagents Used in Immunogenicity Analysis: Case Studies from NAb Assays
Favorite
11:30 AM – 12:30 PM
ET
(M1130-01-08) Establishment of a Generic ADA Assay for Detection of Anti-Drug Antibody Specific to Human IgG Derived Drug Candidate in Murine Serum Samples
Favorite
11:30 AM – 12:30 PM
ET
(M1130-01-09) Development of an In Vitro Cell Culture Model for Evaluation of Influenza Vaccine Formulated Using Spray-Dried Albumin Nanoparticles
Favorite
1:30 PM – 2:30 PM
ET
(M1330-01-01) Developing a Generic ADA Assay for the Detection of Circulating Immune Complexes Using a Fully Automated Microfluidic Immunoassay System
Favorite
1:30 PM – 2:30 PM
ET
(M1330-01-02) A Robust Adoptive Cell Therapy Phenotyping Panel for Assessing Cerebrospinal Fluid During and After Neurotoxicity by Flow Cytometry
Favorite
1:30 PM – 2:30 PM
ET
(M1330-01-03) FM1000 Surfactant is Compatible with Downstream Bioprocessing
Favorite
1:30 PM – 2:30 PM
ET
(M1330-01-04) High-Throughput and Selective LC-MS Quantitation of SMARCA2/4 for SMARCA2 Targeted Protein Degrader Cross-Species Pharmacodynamics Analysis
Favorite
1:30 PM – 2:30 PM
ET
(M1330-01-05) Application of Mitra Microsampling for the Quantitative Bioanalysis of Antisense Oligonucleotides
Favorite
1:30 PM – 2:30 PM
ET
(M1330-01-06) In Vitro Assessment of Physicochemical Properties of Biologics for the Early Identification of Pharmacokinetic Liabilities in a Developability Workflow
Favorite
1:30 PM – 2:30 PM
ET
(M1330-01-07) A Translational Approach for Measuring Bi-specific Anti-Drug Antibodies in Non-Clinical Studies Using a Drug Tolerant Generic Plug and Play Format
Favorite
1:30 PM – 2:30 PM
ET
(M1330-01-08) Comparing the Efficacy of Intranasal Midazolam, Diazepam and Lorazepam as First-Line Treatments of Acute Seizures: Pilot Investigation in Pilocarpine-Induced Mice Model
Favorite
2:30 PM – 3:30 PM
ET
(M1430-01-01) Discrepancies in Adeno-Associated Virus Serotype and Isotype Characterization Positivity Rates in Cynomolgus Serum
Favorite
2:30 PM – 3:30 PM
ET
(M1430-01-02) Approaches for Reducing the Environmental Impact and Increasing the Throughput of Bioanalytical LC Separations
Favorite
2:30 PM – 3:30 PM
ET
(M1430-01-03) Achieving Drug Tolerance in a Multiplexed Neutralizing Antibody Assay (nAb) Using Competition and Heat Solid Phase Extraction (SPE) Conditions
Favorite
2:30 PM – 3:30 PM
ET
(M1430-01-04) Brain-Targeted Delivery of Plasmid DNA Encoding for Angiotensin II Receptor shRNA to Manage Neurogenic Hypertension
Favorite
2:30 PM – 3:30 PM
ET
(M1430-01-05) Immunocapture LC-MS/MS Assay for the Biomarker, Troponin Fast (TNNI2) Using a Specific Antibody
Favorite
2:30 PM – 3:30 PM
ET
(M1430-01-06) Bridging of a Duplex to Singleplex bDNA Method to Quantitate mRNA from LNP-mRNA-ABC in Human Serum
Favorite
2:30 PM – 3:30 PM
ET
(M1430-01-08) Antibody Titration: Titer Cut-Point or Screening Cut-Point: Which One Is a Practical Option?
Favorite
Back to Top
